



SpinalCyte Announces New Australian Patent

December 11, 2019 HOUSTON, TX--SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced the issuance of a new Australian Patent. The company's patent portfolio now includes 174 U.S. and international patents issued and/or pending which are focused on the clinical use of fibroblasts.

"This new Australian Patent builds on our cell-based platform for orthopedic procedures and extends our international leading position in cell therapy," said Pete O'Heeron, Chief Executive Officer of SpinalCyte.

"As we continue to expand our cell therapy platform by using adipose cells for generation of chondrocytes, we are building a broadly protected position for our unique technology."

Australian Patent No. 2014281818 titled "Adipose Cells For Chondrocyte Applications," describes methods to differentiate adipose derived fibroblast cells into chondrocytes using intermittent hydrostatic pressure and hypoxia.

About Degenerative Disc Disease

Degenerative disc disease (DDD) is a condition in which a patient's spinal disc breaks down and can begin to collapse. It is estimated that 85% of people over the age of 50 have evidence of disc degeneration and over 1.3 million procedures a year are performed to treat the disease. The most common treatments for patients with DDD are either discectomy or spinal fusion. Discectomy is the partial or full removal of the degenerated disc to decompress and relieve the nervous system but can cause long term spinal pain. In a spinal fusion procedure, the entire disc is removed and the two adjacent vertebrae are fused together. It often increases strain on the adjacent discs and surrounding tissues leading to further degeneration.

About CybroCell

CybroCell is the first off-the-shelf allogenic human dermal fibroblast (HDF) product for the treatment of degenerative disc disease. SpinalCyte's Phase 1/Phase 2 clinical trial for injected human dermal fibroblasts in the treatment of DDD demonstrated after 12 months, patients injected with CybroCell had sustained improvement in pain relief and increased back mobility.

About SpinalCyte

Based in Houston, Texas, SpinalCyte, LLC, is a regenerative medicine company developing an innovative solution for spinal replacement using human dermal fibroblasts. Currently, SpinalCyte holds 60 U.S. and international issued patents and has filed for an additional 110+ patents pending and issued across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure and Heart Failure. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement in cell therapy. Visit www.spinalcyte.com.

Contact:

Clinical Contact: info@spinalcyte.com



Australian Government

IP Australia

CERTIFICATE OF GRANT STANDARD PATENT

Patent number: 2014281818

The Commissioner of Patents has granted the above patent on 5 December 2019, and certifies that the below particulars have been registered in the Register of Patents.

Name and address of patentee(s):

Spinalcyte, LLC of 17300 El Camino Real, Suite 110 Houston TX 77058 United States of America

Title of invention:

Adipose cells for chondrocyte applications

Name of inventor(s):

O'Heeron, Pete

Term of Patent:

Twenty years from 13 June 2014

Priority details:

Number
61/836,975

Date
19 June 2013

Filed with
US



Dated this 5th day of December 2019

Commissioner of Patents

PATENTS ACT 1990

The Australian Patents Register is the official record and should be referred to for the full details pertaining to this IP Right.